Antibodies from rabbits improve survival and relapse outcomes of leukemia and …Medical Xpress… retrospectively compared the outcomes of 50 patients who received rabbit anti-thymocyte globulin (ATG) before receiving a transplant of stem cells from a…
Dr Reddy's plans to launch biosimilars in developed marketsHindu Business LineAt present, the biosimilar portfolio of the Hyderabad-based company comprises Filgrastim, peg-filgrastim, Rituximab and Darbepoetin alfa. Dr Reddy's global biosimilar…
Janssen-Cilag International withdraws application for Velcade (bortezomib)Express PharmaJanssen-Cilag International NV on September 2, 2011, submitted an application to extend the marketing authorisation for Velcade in combination with rituximab for th…
J&J pulls file to extend Velcade's use in EUPharma TimesThe drugmaker was seeking approval for the use of Velcade in combination with rituximab as a treatment for patients with relapsed follicular non-Hodgkin lymphoma. However, in a statement r…
Janssen withdraws attempt to extend Velcade indication in EUPMLiVEThe Johnson & Johnson division had submitted an application to the European Medicines Agency (EMA) in September 2011 to consider the drug's use in combination with rituximab for …
EMA: Janssen-Cilag has Withdrew Extension Application for VelcadeWall Street Journal2, 2011, submitted an application to extend the marketing authorization for Velcade in combination with rituximab for the treatment of patients with relapsed follicular…
Long-Term Rituximab Safe for Patients With Wegener'sDoctors LoungeRepeated and prolonged use of rituximab for B-cell depletion to treat relapses or maintain remission is safe and effective in patients with refractory granulomatosis with polyangiiti…
Long-term rituximab safe for patients with wegener'sMedical Xpress(HealthDay) — Repeated and prolonged use of rituximab for B-cell depletion to treat relapses or maintain remission is safe and effective in patients with refractory granulomatosis w…
Despite likely new MS drugs, US neurologists continue to see significant near …The Pharma LetterIn fact, interest in BG-12, along with Biogen Idec's PEG-Avonex, Abbott/Biogen Idec's daclizumab and Roche/Genentech's ocrelizumab, has increa…
BioTrends Research GroupPosted on:28 Jun 12PharmiWeb.com (press release)In fact, interest in BG-12, along with Biogen Idec‚Äôs PEG-Avonex, Abbott / Biogen Idec‚Äôs daclizumab and Roche / Genentech‚Äôs ocrelizumab, has increased significantl…